TARA
NASDAQProtara Therapeutics Inc.
Price$4.04-0.17 (-4.15%)
01:30 PM07:45 PM
News · 26 weeks50-37%
2025-12-142026-06-07
Mix1790d
- SEC Filings8(47%)
- Other6(35%)
- Insider3(18%)
Latest news
25 items- INSIDERChief Commercial Officer Conkling William covered exercise/tax liability with 6,008 shares, decreasing direct ownership by 8% to 69,992 units (SEC Form 4) to satisfy withholding tax4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- SECSEC Form 424B5 filed by Protara Therapeutics Inc.424B5 - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECSEC Form EFFECT filed by Protara Therapeutics Inc.EFFECT - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRProtara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHANEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET. A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation. About Protara Therapeutics, Inc. Protara is a clinic
- PRProtara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that it will host a virtual webinar for the investment community at 4:30 pm ET on Tuesday, May 19, 2026. The agenda will include an overview of Lymphatic Malformations (LMs), key opinion leader (KOL) perspectives on the burden of disease and current treatment landscape, the market opportunity and regulatory path for TARA-002 and a review of cl
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
- PRProtara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBCTARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company remains on track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced positive updated 12-month data from Cohort A of the ong
- SECSEC Form 10-Q filed by Protara Therapeutics Inc.10-Q - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRProtara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdateThe Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion leader (KOL) perspectives on May 19, 2026 at 4:30 pm ET Interim safety and durability data from STARBORN-1 trial of TARA-002 in LMs to be presented at the International Society for the Study of Vascular Anomalies (ISSVA) World Congress 2026 in May Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial and initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Presenting updated 12-month data from Phase 2 ADVANCED-2 t
- SECSEC Form DEFA14A filed by Protara Therapeutics Inc.DEFA14A - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECSEC Form DEF 14A filed by Protara Therapeutics Inc.DEF 14A - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRProtara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual MeetingNEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated, interim data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial evaluating TARA-002 in patients with BCG-Naïve non-muscle invasive bladder cancer (NMIBC) will be featured during a poster session at the upcoming American Urological Association (AUA) 2026 Annual Meeting taking place from May 15, 2026 to May 18, 2026 in Washington, DC. The presentation will include data from the abstract published on the AUA website, as well as updated safety
- SECSEC Form PRE 14A filed by Protara Therapeutics Inc.PRE 14A - Protara Therapeutics, Inc. (0001359931) (Filer)
- INSIDERSEC Form 4 filed by Zummo Jacqueline4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Zummo Jacqueline4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECSEC Form 10-K filed by Protara Therapeutics Inc.10-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRProtara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateReported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 On track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations (LMs); regulatory update expected in 1H 2026 Expect to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 2H 2026 Co
- SECSEC Form 424B7 filed by Protara Therapeutics Inc.424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)
- ANALYSTAnalyst initiated coverage on Protara Therapeutics with a new price targetAnalyst initiated coverage of Protara Therapeutics with a rating of Overweight and set a new price target of $27.00
- SECSEC Form SCHEDULE 13G filed by Protara Therapeutics Inc.SCHEDULE 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRTARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder CancerFavorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in patients with high-risk Non-Muscle Inva
TARA FAQ
7 questionsWhat does Protara Therapeutics Inc. do?
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May...Where does TARA stock trade?
Protara Therapeutics Inc. (TARA) is listed on NASDAQ.What sector and industry is TARA in?
Protara Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Protara Therapeutics Inc. go public?
Protara Therapeutics Inc. (TARA) completed its IPO in 2014.What are analysts saying about TARA?
Protara Therapeutics Inc. has had 6 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $2700.00 price target on 2026-03-04. Recent price targets range from $1200.00 to $3400.00.What companies are similar to TARA?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare TARA side-by-side with any of them on Quantisnow.How can I track TARA on Quantisnow?
Quantisnow aggregates Protara Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TARA to receive live email and push alerts on every new disclosure.